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a b s t r a c t
Co-infection of inﬂuenza A and B viruses (IAV and IBV) results in marked decreases in IAV replication.
Multiple mechanisms have been proposed for this phenomenon. Recently, we reported that IBV
nucleoprotein (BNP) alone can suppress IAV replication and proposed an inhibition model in which
BNP binds IAV nucleoprotein (ANP) and disrupts IAV polymerase complexes. Here, using mutagenesis
and co-immunoprecipitation, we determined the protein motifs mediating the intertypic ANP–BNP
complex and showed that it speciﬁcally interferes with ANP's interaction with the PB2 subunit of the IAV
polymerase but not with the other subunit PB1. We further demonstrated that BNP only suppresses
growth of IAVs but not other RNA viruses. However, different IAV strains display varied sensitivity
toward the BNP's inhibitory effect. Together, our data provide mechanistic insights into intertypic
nucleoprotein complex formation and highlight the role of BNP as a potential broad-spectrum anti-
IAV agent.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Type A and B inﬂuenza viruses (IAV and IBV) are morphologi-
cally indistinguishable and possess similarly-organized eight-seg-
mented RNA genomes that encode similar sets of proteins (Ruigrok
et al., 1984; Palese and Shaw, 2006). Despite their close phylogenic
relationship, IAV and IBV have not generated natural or synthetic
intertypic reassortants upon co-infection (Tobita and Ohori, 1979;
Iwatsuki-Horimoto et al., 2008). Moreover, IBV can substantially
inhibit growth of IAV. These phenomena, collectively termed
intertypic interference, were ﬁrst reported in 1954 (Gotlieb and
Hirst, 1954) and have since been conﬁrmed in numerous strains of
IAV and IBV (Tobita and Ohori, 1979; Mikheeva and Ghendon,
1982; Kaverin et al., 1983; Aoki et al., 1984). Several mechanisms
have been proposed for intertypic interference. Initial works
identiﬁed primary transcription as the point where interference
occurs, leading to a steep decline in viral protein synthesis
(Mikheeva and Ghendon, 1982; Aoki et al., 1984). Ill-matched
binding between the non-coding regions of some viral RNA (vRNA)
segments and the polymerase complexes from different types of
inﬂuenza viruses could also prevent intertypic genetic reassort-
ment (Muster et al., 1991; Baker et al., 2014). More recent studies
reported incompatibility between IAV and IBV polymerase sub-
units, resulting in inefﬁcient intertypic polymerase complexes and
reduced vRNA production (Iwatsuki-Horimoto et al., 2008;
Wunderlich et al., 2010). These mechanisms are not mutually
exclusive, and they all pointed to the viral polymerase complex as
a critical factor in intertypic interference.
For both IAV and IBV, the polymerase complex is bound at the
end of each vRNA segment and consists of three protein subunits:
polymerase basic 1 and 2 (PB1 and PB2) and polymerase acidic
(PA) (Klumpp et al., 1997; Coloma et al., 2009; Arranz et al., 2012).
The rest of the vRNA strand is encapsidated by multimers of
nucleoproteins (NP), primarily formed by insertion of the C-
terminal ‘tail loop’ of one NP molecule into the next (Pons et al.,
1969; Ye et al., 2006; Ng et al., 2008, 2012). The region that
surrounds and donates interaction sites to the tail loop comprises
discontinuous portions of NP and will be collectively called the
‘tail-loop receptor’ for short. An example of these critical tail loop–
tail-loop receptor interactions is the highly conserved salt bridge
between R472 and E395 (BNP numbering) (Fig. 1A; Ng et al., 2012).
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Additional aromatic residues on the tail loop such as F468 also
contribute important van der Waal interactions. Recent studies
have also implicated the role of phosphorylation in regulating NP
multimerization (Turrell et al., 2015; Mondal et al., 2015).
Although high-resolution details are still lacking, biochemical
experiments and cryo-electron microscopy have suggested that
NP interacts with PB1 and PB2 within the viral ribonucleoprotein
(vRNP) complexes (Arranz et al., 2012; Biswas et al., 1998). More-
over, NP performs multiple functions, including nuclear import
and export of vRNA and regulation of transcription and replication,
by interacting with several partner proteins of both viral and
cellular origins (Biswas et al., 1998; Portela and Digard, 2002;
Shapiro and Krug, 1988; Cao et al., 2014). As per these crucial roles,
NP has been a prime target for cellular antiviral mechanisms along
with inﬂuenza antiviral drug research (Verhelst et al., 2012; Turan
et al., 2004)).
Recently, we have suggested that IAV nucleoprotein (ANP) is
also a target of a novel antiviral mechanism mediated by its close
cousin, IBV nucleoprotein (BNP) (Wanitchang et al., 2012; Jaru-
ampornpan et al., 2014). First, we observed suppressed IAV
polymerase activity and a moderate reduction in IAV replication
in the presence of BNP (Wanitchang et al., 2012). Based on
Fig. 1. BNP oligomerization motifs are critical in IAV polymerase inhibition. (A) Crystal structure of BNP (PDB ID: 3TJ0) shows interactions of the tail loop (gold) of one
monomer and the tail-loop receptor (purple) of a neighboring monomer. Important residues are represented by sticks. Dash lines represent a highly-conserved salt bridge
between E395 and R472. (B) Nuclear localization of BNP mutants. HEK293T cells were transfected with pHW2000-BNP-Myc and subjected to immunoﬂuorescence with anti-
Myc antibody and FITC-conjugated goat-anti-mouse antibody. Scale bar, 10 μm. IBV polymerase activity was determined by minigenome assay as described in section
Materials and Methods. Values are average7S.D. and are relative to wild-type BNP. (C) IAV polymerase inhibition assay was performed as described in section Materials and
Methods. Values are relative to IAV polymerase activity in the presence of the pHW2000 vector (lane ‘–’). Error bars indicate S.D. of three independent experiments. (D) Co-IP
with anti-ANP antibody was performed on lysates prepared from HEK293T cells transfected with pHW2000 plasmids expressing ANP and BNP (WT or mutants; 500 ng
each). IP, immunoprecipitate complex; input, 10% of the input lysate. (E) Concentration dependence of BNP inhibitory effects was performed with varying amount of
pHW2000-BNP-WT (black) or E395A (gray) in IAV minigenome assay as described in section Materials and Methods.
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biochemical evidence, we further suggested that BNP inhibits IAV
polymerase activity by non-functionally interacting with ANP and
interfering with vRNP complex formation (Jaru-ampornpan et al.,
2014). However, many mechanistic questions still remain. Do
heterotypic ANP–BNP interaction require the same set of interac-
tions mediating homotypic NP oligomers? Does BNP disrupt ANP's
interactions with both PB1 and PB2? How does BNP compete with
polymerase subunit(s) for ANP? More importantly, potency and
speciﬁcity of BNP's antiviral effect have yet to be rigorously
examined. These details will augment our understanding of BNP's
virus suppression mechanism and will be important for its
potential use as an antiviral agent.
In this work, we present evidence that BNP homo-oligomerization
motifs are necessary for its inhibitory effect most likely through their
involvement in heterotypic NP binding. We showed that BNP can
disrupt the ANP–PB2 interaction but does not interfere with PB1
binding in the absence of other polymerase subunits. Lastly, we
demonstrated that BNP potently and speciﬁcally inhibits growth of
different IAV strains. Together, these results shed new mechanistic
light on our understanding of intertypic interference mediated by
BNP and provide knowledge basis for future manipulation of BNP for
anti-IAV use.
Results
Tail loop and tail-loop receptor of BNP are critical for ANP binding
and IAV polymerase inhibition
In previous work, we showed that nuclear localization and
RNA-binding motifs are important for BNP's inhibitory effect (Jaru-
ampornpan et al., 2014). In this work, we explored if and how
oligomerization ability of BNP was necessary for its inhibitory
effect on IAV polymerase. We studied three representative BNP
oligomerization mutants. R472A and F468S are located in the tail
loop, whereas E395A represents a tail-loop receptor mutant
(Fig. 1A). These mutants severely impaired BNP oligomerization
and IBV polymerase activity (Ng et al., 2012). We asked if they still
inhibited IAV polymerase. We ﬁrst conﬁrmed that all BNP variants
are normally localized to the nucleus (Fig. 1B). Then, using IAV
minigenome assay, we showed that BNP-R472A and BNP-F468S
had no effect, while BNP-E395A displayed a reduced inhibitory
effect on IAV polymerase activity (Fig. 1C).
We asked whether these residues, especially those in the tail
loop, are required for IAV polymerase inhibition because they are
utilized in intertypic NP oligomerization. To test this, cell lysates
prepared from HEK293T cells transfected with a pair of plasmids
encoding ANP and each of the BNP variants were co-
immunoprecipitated by anti-ANP. The tail loop mutants, R472A
and F468S, displayed marked decreases in ANP binding, correlat-
ing with their inability to suppress IAV polymerase activity
(Fig. 1D). These data suggest that BNP utilizes interactions from
the tail loop in both homo- and heterotypic oligomerization.
Interestingly, BNP-E395A also showed absence of ANP interac-
tion in our co-immunoprecipitation conditions but still retained
some, albeit substantially reduced, inhibitory effect (Fig. 1D and C).
This is a surprising outlier to our previous inhibition model
(Jaru-ampornpan et al., 2014), implying a possibility in which a
‘non-interacting’ BNP could somehow interrupt the IAV polymer-
ase complex. Nevertheless, the lingering effect of BNP-E395A
exhibited concentration dependence similarly displayed by wild-
type BNP but with much smaller magnitudes, suggesting that
BNP-E395A inhibits IAV polymerase possibly through a competi-
tive mechanism similar to wild-type BNP but much less efﬁciently
(Fig. 1E). Although not deﬁnitively, this observation argues for
weak or transient interaction between BNP-E395A and ANP
that may be undetectable by our current binding assay but
still results in IAV polymerase inhibition (more in section
Discussion).
The outlying behavior of BNP-E395A prompted us to further
interrogate our original hypothesis that the intertypic NP complex
underlies BNP's inhibitory effect. To this end, we made additional
novel mutations around the tail loop–tail loop receptor interface
to test whether there is a correlation between ANP binding and
the IAV polymerase inhibitory effect. D380 and G391 cap each end
of the helix adjacent to the crucial E395 loop, whereas P444 and
R447 reside in the loop that folds around the tail loop on the
opposite side (Fig. 2A, left and right panels respectively; Ng et al.,
2012). G431 is situated on the base of a small β-strand further
away and does not seem to participate in homo-oligomerization
(Ng et al., 2012) and was chosen as a control. We conﬁrmed that
these residues were not variations between IBV strains, as they
were conserved among 1912 available BNP sequences from the
inﬂuenza virus resource database (Bao et al., 2008).
These BNP mutants are nuclear localized but differentially
affect IBV polymerase activity (Fig. 2B). While G431A mutation
increases IBV polymerase activity by almost two-fold, others
showed defects in IBV polymerase activity ranging from 80%
reduction in the case of R447A to almost no activity in others
(Fig. 2B). Next, we performed IAV minigenome assays in the
presence of the plasmid expressing each BNP variant. D380A and
G391A showed almost no inhibitory effect on IAV polymerase
(Fig. 2C). These BNP mutants were barely observed in a pulldown
by anti-ANP, suggesting signiﬁcant decreases in ANP binding
(Fig. 2D). Mutations on the opposite side of the tail-loop receptor
showed variations in their abilities to inhibit IAV polymerase and
to interact with ANP (Fig. 2C and D). While G431A and R447A
exhibited wild-type level of inhibition, P444A could hardly inhibit
IAV polymerase (Fig. 2C). Co-immunoprecipitation results
reﬂected the trend observed in polymerase inhibition; P444A
showed no ANP binding, in contrast to strong ANP binding
observed with wild-type, G431A and R447A BNP (Fig. 2D).
Together, these results revealed additional residues in BNP's tail-
loop receptor that are essential for intertypic NP interactions and
IAV polymerase inhibition. With the exception of E395A, these
mutants, along with those from the above section and the
previous report (Jaru-ampornpan et al., 2014), displayed a strong
correlation between ANP binding and IAV polymerase inhibition.
Phosphorylation of BNP do not abolish heterotypic NP complex
formation
Recent work has identiﬁed phosphorylation sites for inﬂuenza
virus nucleoproteins and demonstrated that phosphorylation is an
important regulator of nucleoprotein oligomerization (Turrell
et al., 2015; Mondal et al., 2015). Phosphomimetic mutations in
BNP (S226D or S463D) disrupt BNP's tail loop–tail-loop receptor
interactions and attenuated IBV replication (Mondal et al., 2015). To
test phosphorylation's effect on heterotypic NP complex formation,
we mutated these two critical serines, S226 and S463, to aspartate to
mimic the phosphorylated state of BNP. Both BNP-S226D and BNP-
S463D are localized in the nucleus (Fig. 3A). BNP-S463D showed
reduced IBV polymerase activity, while the effect of the S226D
mutation was more pronounced (Fig. 3A). These results are consis-
tent with the observations that recombinant IBVs containing the
S463D mutation showed attenuated growth while that containing
the S226D could not be rescued (Mondal et al., 2015).
Interestingly, BNP-S226D and BNP-S463D caused substantial reduc-
tion of IAV polymerase activity (Fig. 3B). Co-immunoprecipitation by
anti-ANP antibody revealed that both BNP mutants could be observed
in the elution, suggesting that they could interact with ANP (Fig. 3C).
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This was perhaps surprising in light of recent characterization of these
mutants as defective in homotypic oligomerization (Mondal et al.,
2015). Nevertheless, the results in this part further support the notion
that the ANP–BNP interaction is critical for IAV polymerase inhibitory
effect of BNP.
BNP timing and expression level determine magnitude of its effect on
IAV growth suppression
We next evaluated the effect of the intertypic NP complex in
viral infection contexts. For precise control, we chose to use a non-
Fig. 2. Residues in the BNP tail-loop receptor contribute to intertypic NP interactions. (A) Structural organization around the BNP tail loop (gold; PDB ID: 3TJ0). Mutated
residues are highlighted in sticks. For these BNP mutants, cellular localization, IBV polymerase activity, IAV polymerase inhibition and ANP interaction were determined by
immunoﬂuorescence (B; scale bar, 10 μm), IBV minigenome assay (B; values are average7S.D. and are relative to wild-type BNP), IAV minigenome assay (C) and co-IP by
anti-ANP antibody (D), respectively, as described in section Materials and Methods.
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interacting BNP mutant as a baseline for comparison. Since all
these mutants disable IBV polymerase, rescuing mutant IBV
particles for co-infection experiment was impossible. To circum-
vent this problem, we turned to a PB2-knockout IAV system that
allows expression of a foreign protein (Uraki et al., 2013). Brieﬂy,
the PB2 coding sequence in the PR8 virus was replaced with BNP
(wild-type or mutants) coding sequences. Reverse genetics was
performed to generate rgΔPB2-PR8-BNP IAVs encoding both ANP
and BNP (Fig. 4A). Modiﬁed MDCK cells expressing PB2 (MDCK-
PB2) were infected with these chimeric viruses, and BNP expres-
sion in infected cell extracts was conﬁrmed (Fig. 4B).
To analyze viral growth, MDCK-PB2 cells were infected with
chimeric IAVs harboring different BNP variants (MOI¼0.001), and
infectious viral progenies in supernatants were quantiﬁed by
plaque assay. As a control, the growth of ΔPB2-PR8-mCherry,
the chimeric virus harboring the mCherry gene, was analyzed in
parallel. Barely one-log difference in growth was observed
between ΔPB2-PR8-BNP and ΔPB2-PR8-mCherry, and growths
of other chimeric viruses were in-between (Fig. 4B). This small
effect is reminiscent of a moderate suppression of IAV growth seen
in MDCK cells transduced by pseudotyped retrovirus expressing
BNP in previous work (Wanitchang et al., 2012). Still, this is
surprising, considering how largely IAV polymerase activity was
reduced by BNP protein in in vitro experiments (Fig. 1).
To independently quantify the biological impact of ANP–BNP
interaction, we examined IAV growth in modiﬁed MDCK cell lines
stably expressing either wild-type or non-interacting mutant BNPs
(E395A, F468S, R472A) (Fig. 4C). Western blotting conﬁrmed
similar expression of all BNP variants (Fig. 4D). Notably, these
MDCK cell lines expressed much higher levels of BNP proteins
compared to the MDCK-BNP cell line used in previous work,
possibly due to the efﬁciency of lentiviral transduction (data not
shown; Wanitchang et al., 2012). For viral growth kinetics analysis,
supernatants from PR8-infected MDCK cells and those harboring
each of the BNP variants (MOI¼0.001) were harvested at 12 and
24 h post-infection and assessed for viral titers in fresh MDCK
cells. The viruses retrieved from MDCK, MDCK-BNP F468S, and
MDCK-BNP R472A cells grew to equivalent titers (Fig. 4D). Remark-
ably, we observed large growth retardation (ﬁve-log) in MDCK-
BNP cells, whereas intermediate growth delay was observed in
MDCK-BNP E395A cells (Fig. 4D).
Interestingly, the viral growth inhibitory effect observed with
MDCK-BNP cells was much more pronounced than that observed
in the case of ΔPB2-PR8-BNP virus (cf. Fig. 4D and B). We
suspected that this discrepancy might stem from unequal BNP
expression between the two systems. Indeed, we observed notice-
ably larger BNP expression in the cell lines than in cells infected
with the chimeric viruses (Fig. 4E, ‘cl’ vs. ‘cv’ lanes). In the case of
wild-type BNP, comparing expression levels in these conditions
might have been complicated by BNP’s own inhibitory effect on
the ΔPB2-PR8-BNP virus, as a faint band for ANP could only be
observed upon long exposure (data not shown). Nevertheless, we
could infer difference in expression levels from BNP mutants
which have negligible effects on viral growth in either system
(Fig. 4E, F468S and R472A). It is conceivable that timing of BNP
expression might also contribute to the discrepancy. In the case of
chimeric viruses, BNP expression is initiated only upon primary
transcription by the incoming viruses, whereas BNP is already
present in the MDCK-BNP cell line prior to infection. Overall, the
data in this part implied that BNP expression levels, and also
perhaps its timing, are critical for its IAV inhibitory effect, once
again arguing for the competitive nature of the inhibition mechan-
ism. Notably, these results also proved that BNP was capable of
enormous viral growth suppression upon a suitable expression
level, showcasing its potency as a strong antiviral protein.
ANP reciprocally engages BNP via its oligomerization motifs
We reciprocally identiﬁed the ANP motifs necessary for inter-
typic NP complex formation. To this end, we generated ANP-R416A
Fig. 3. Phosphomimetic BNP mutants retain ANP binding and inhibitory effect toward IAV polymerase. For BNP-S226D and BNP-S463D, cellular localization, IBV polymerase
activity, IAV polymerase inhibition and ANP interaction were determined by immunoﬂuorescence (A; scale bar, 10 μm), IBV minigenome assay (A; values are average7S.D.
and are relative to wild-type BNP), IAV minigenome assay (B) and co-IP by anti-ANP antibody (C), respectively, as described in section Materials and Methods.
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and ANP-E339A, the reciprocal tail loop and tail-loop receptor
mutants, and tested their ability to bind BNP. HEK293T cells were
co-transfected with plasmids expressing Myc-tagged BNP and
each of the ANP variants. Co-immunoprecipitation with anti-Myc
antibody showed impairment in BNP binding by both ANP
mutants compared to wild-type ANP (Fig. 5A). In a similar setting,
ANP-Myc indistinguishably pulled down all ANP variants (wild-
type, E339A or R416A), suggesting that, at least, the binary
complexes between ANP-Myc and these ANP mutants could
be detected by our co-immunoprecipitation conditions
(Supplementary Fig. 1). This pattern is in stark contrast to severe
loss of ANP mutants in the complex pulled down by BNP-Myc,
suggesting that these ANP mutants could not bind BNP-Myc. The
results in this section suggested that ANP's homo-oligomerization
motifs are necessary for intertypic NP interaction.
Other mutations that could essentially lock ANP in either the
monomeric or oligomeric states have been reported (Chenavas et al.,
2013). A phosphorylation site mutation (S165D) abolishes ANP
Fig. 4. Anti-IAV effect of BNP depends on timing and expression level of BNP. (A) Experimental scheme for infection of ΔPB2-PR8-BNP IAV in MDCK-PB2 cells. (B) Growth
analysis of ΔPB2-PR8 viruses bearing different genes in MDCK-PB2 cells (MOI¼0.001). (C) Experimental scheme for infection of PR8 in BNP-expressing MDCK cells.
(D) Growth analysis of PR8 in MDCK cells or MDCK cells expressing BNP variants (MOI¼0.001). For (B) and (D), error bars represent S.D. from three independent infections.
Infected cell lysates were probed with anti-BNP antibody to check BNP expression. (E) Western blot analysis of BNP expression in MDCK cells infected with ΔPB2-PR8-BNP
chimeric viruses (‘cv’) and MDCK-BNP cells infected with PR8 (‘cl’). Equal cells (5105 cells/well) and equal MOI (0.001) were used.
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oligomerization by precluding proper tail loop–tail-loop receptor
interactions (Chenavas et al., 2013; Turrell et al., 2015; Mondal et al.,
2015). On the other hand, ANP-Y148A exists predominantly in an
oligomeric state in biochemical characterization (Tarus et al., 2012). Its
cellular state, oligomerization dynamics and biological signiﬁcance
are unclear, but the recombinant virus harboring this mutation could
not be rescued (Li et al., 2009). To test how oligomeric states of ANP
affect BNP binding, we performed co-immunoprecipitation with anti-
Myc antibody on lysates containing Myc-tagged BNP and each of
these ANP variants. The obligatory monomeric ANP-S165D was barely
visible in co-IP elution, whereas the ultra-stable oligomeric ANP-
Y148A could be captured slightly less compared to wild-type ANP
(Fig. 5B). These results suggest that oligomerization dynamics is
important to both intertypic and homotypic oligomerization. Alter-
natively, S165 or phosphorylation of ANP might directly mediate
intertypic interactions.
ANP utilizes distinct residues in binding to BNP and PB2
Previously, we proposed a model in which BNP's interaction
with ANP interferes with vRNP complex formation. In the presence
of all polymerase subunits, we showed that increasing BNP results
in diminishing polymerase subunits (PB2) co-precipitating with
ANP (Jaru-ampornpan et al., 2014). However, it is not known
whether BNP could disrupt the pairwise ANP–PB2 interaction.
Furthermore, does BNP also interrupt ANP’s interaction with other
polymerase subunits? To this end, we co-expressed ANP with
either FLAG-tagged PB1 or PB2, the two IAV polymerase subunits
reported to bind ANP (Biswas et al., 1998), in the presence of
increasing BNP and performed co-immunoprecipitation using
anti-ANP antibody. The amount of PB2-FLAG in the co-IP complex
was correspondingly diminished upon increasing BNP, as pre-
viously observed in the context of a complete polymerase complex
(Fig. 6A and C). In contrast, the amount of PB1-FLAG pulled down
by ANP did not signiﬁcantly change in the presence of increasing
BNP (Fig. 6B and C). These results suggested that BNP speciﬁcally
disrupts ANP–PB2 interaction even without other vRNP subunits
but does not interfere with PB1 binding.
To test if BNP competes with PB2 for the same interaction sites
on ANP, which is the simplest model of interference, we studied
ANP mutants previously characterized for polymerase binding
(Marklund et al., 2012; Gui et al., 2014). We veriﬁed these mutants'
effects on ANP–PB2 interaction in our experimental conditions and
found that D88A and WR207,208AA showed severe and moderate
loss in PB2 binding, respectively (Fig. 6D and F). Co-
immunoprecipitation of the lysates containing Myc-tagged BNP
and each of the ANP variants (wild-type, D88A and WR207,208AA)
with anti-Myc antibody revealed no drastic difference in the
amount of the co-eluted ANP (Fig. 6E and F). It is arguable that
ANP-D88A might bind BNP-Myc slightly less well, but this small
decrease did not reﬂect the severe loss of PB2 binding exhibited by
this mutant in our experimental conditions (Fig. 6F). These results
implied that ANP utilizes distinct interaction sites to bind BNP
and PB2.
BNP's antiviral effect is speciﬁc to IAV but can vary over different
strains
We next asked how other IAV strains respond to BNP. To this
end, we repeated the experiments with additional strains: A/
Uruguay/716/2007 (H3N2) and A/duck/Suphanburi/AI157/2005
(H6N1). Co-immunoprecipitation showed that Myc-tagged ANP
derived from each strain could bind to BNP, but efﬁciency of the
intertypic NP interactions seemed slightly varied (Fig. 7A). Next,
using the minigenome assay, we showed that both H3N2 and
H6N1 polymerases showed substantial reduction in their activities
in the presence of BNP (Fig. 7B). Although still quite efﬁcient,
inhibition observed with H3N2 polymerase was smaller than those
observed with H1N1 and H6N1 polymerases. To examine growth
suppression by BNP, MDCK and MDCK-BNP cells were infected
with each strain (MOI¼0.001), and viral progenies were assessed
by plaque assay. Growth suppression of H3N2 was less pro-
nounced than that of H1N1, consistent with the in vitro results
from polymerase inhibition (Fig. 7C). These results suggested that
BNP has a potential to broadly suppress several IAV strains, albeit
with different efﬁciency.
Lastly, to demonstrate speciﬁcity of BNP's inhibitory effect, we
tested if BNP could stall growth of other RNA viruses. We infected
MDCK and MDCK-BNP cells with vesicular stomatitis virus (VSV;
MOI¼0.001) and compared VSV replication in these cells. VSV could
efﬁciently replicate in MDCK cells, acquiring reasonable titers at
104 PFU/ml after 12 h (Fig. 7D). VSV grew equally well in MDCK-BNP
cells, showing no sign of growth inhibition (Fig. 7D). These results
suggested that BNP's antiviral effect is not generalized.
Discussion
One of the long-standing observations about intertypic inter-
ference is suppression of IAV growth upon co-infection with IBV
(Tobita and Ohori, 1979; Mikheeva and Ghendon, 1982; Kaverin et
al., 1983; Aoki et al., 1984; Wanitchang et al., 2012). In our previous
publications, we proposed a model in which BNP mediates IAV
growth suppression via interaction with ANP and disruption of IAV
Fig. 5. ANP homo-oligomerization motifs are important for intertypic NP complex
formation. HEK293T cells were co-transfected with plasmids expressing BNP-Myc
and each of the ANP variants (500 ng each). Cell lysates were subjected to co-IP by
anti-Myc antibody and analyzed by western blots with indicated antibodies. IP,
immunoprecipitate complex; input, 10% of the input lysate. (A) Mutations on the
tail loop and the tail-loop receptor showed severe defects in intertypic NP binding.
(B) Mutations that modulate the oligomeric states of ANP displayed different BNP
binding behaviors. In the last lane, cells were transfected with pHW2000-BNP
instead of pHW2000-BNP-Myc to serve as a negative control for co-IP.
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vRNP complex formation (Wanitchang et al., 2012; Jaru-
ampornpan et al., 2014). As a continuation, we here characterized
molecular interactions mediating this detrimental ANP–BNP inter-
typic interaction and investigated how it disrupts the essential
interactions between ANP and individual polymerase subunits.
In this work, we conﬁrmed that the homo-oligomerization
property of BNP is critical for BNP’s inhibitory effect on IAV
because the same motifs also mediate heterotypic oligomer for-
mation. Early study with the tail-loop truncation mutant sug-
gested that the tail loop was involved in BNP’s inhibitory action.
However, very low expression of this mutant created rooms for
alternative explanations that the lack of IAV polymerase inhibition
might have stemmed from structural and expression concerns
(Wanitchang et al., 2012). In this work, we ruled out these
possibilities by studying point mutations on the tail loop that
have been speciﬁcally described for homo-oligomerization (Ng
et al., 2012). These BNP mutants revealed loss in ANP interaction,
severe defects in IAV polymerase inhibition and no suppression on
IAV growth. Reciprocally, ANP homo-oligomerization mutants
displayed lack of intertypic NP interaction. Additionally, we used
help from the BNP crystal structure to generate several mutations
on the tail-loop receptor side and showed that the ability to
interrupt IAV polymerase activity correlates well with intertypic
NP complex formation. These data together suggest that the tail
loop and the tail-loop receptor areas of BNP are necessary for IAV
polymerase inhibition most likely because they are involved in
formation of ANP–BNP heterotypic complex through a similar
mechanism as homotypic oligomers.
A few observations from our mutagenesis study are worth
noting. First, BNP-E395A showed no ANP binding in our co-
immunoprecipitation experiment but displayed residual inhibitory
effects on IAV polymerase and growth suppression. From our
collection of twelve BNP mutants, this is the only outlier to the
correlation between IAV polymerase inhibition and ANP interac-
tion. Although we could not completely rule out other possibilities,
we are inclined to believe that transient or weak interactions
between ANP and BNP-E395A might evade detection by our
current assay, but the inhibition mechanism proceeds identically
to wild-type BNP albeit with much lower efﬁciency. First, the
inhibition proﬁle of BNP-E395A displays the same competitive
behavior as wild-type, potentially reaching the same level of
inhibition but with a much higher effective concentration to reach
50% inhibition (Fig. 1E). Simplistically, this is a proxy for difference
in binding afﬁnity between the two competitors (wild-type vs.
E395A). Second, a recent report has suggested that the equivalent
mutation in ANP, E339A, acted as a dominant negative in vRNP
formation, indicating that ANP-E339A could be incorporated to
terminate the NP chain but could not function (Turrell et al., 2013).
Likewise, it could be envisioned that BNP-E395A might be incor-
porated to terminate the intertypic NP chain, and the effect of this
binding is only manifested in a polymerase inhibition assay which
might be more sensitive than co-immunoprecipitation in this case.
Another interesting mutation is BNP-R447A, which could inhibit
IAV polymerase but could not support IBV polymerase. This is an
example case that decouples BNP's functionality from its capacity
to suppress IAV replication and helps reﬁne our earlier conclusion
Fig. 6. BNP disrupts ANP–PB2 interaction but not ANP–PB1 interaction. HEK293T cells were co-transfected (500 ng each) with pHW2000-ANP and pHW2000-PB2-FLAG
(A) or pHW2000-PB1-FLAG (B) in the absence or presence of pHW2000-BNP (amount as indicated). Cell lysates were subjected to co-IP by anti-ANP antibody and analyzed
by western blots with indicated antibodies. (C) Quantiﬁcation of PB2-FLAG or PB1-FLAG pulled down by ANP. For each IP reaction, the ‘prey’ band (anti-FLAG) was
normalized by the corresponding ‘bait’ band (anti-ANP) from the same lane. Values are displayed relative to those in the ‘no BNP’ conditions. HEK293T cells were co-
transfected (500 ng each) with pHW2000-ANP (WT, D88A or WR207,208AA) and pHW2000-PB2-FLAG (D) or pHW2000-BNP-Myc (E). Cell lysates were subjected to co-IP by
anti-ANP (D) or anti-Myc (E) antibody and analyzed by western blots with indicated antibodies. (F) Quantiﬁcation of PB2-FLAG or ANP pulled down by ANP or BNP-Myc,
respectively. The ‘prey’ bands (anti-FLAG or anti-ANP) were normalized by their corresponding ‘bait’ bands (anti-ANP or anti-Myc) from the same lane. Values are displayed
relative to those in the ‘WT’ conditions.
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drawn from studying truncation mutants (Wanitchang et al.,
2012). Rather than being full-length and functional, BNP only
needs to correctly localize and bind ANP to suppress IAV poly-
merase activity. Also supporting this notion are the phosphomi-
metic BNP mutants, BNP-S226D and BNP-S463D, that could not
support IBV polymerase function but were able to efﬁciently
suppress IAV polymerase activity. Curiously, they cannot self-
associate but are able to bind ANP (Mondal et al., 2015 and
Fig. 3C). Note that this pattern is in contrast to the phosphomi-
metic ANP mutant which could not retain BNP binding, possibly
suggesting directionality or asymmetry in heterotypic NP complex
formation. These data also imply that there exist small but
important differences in molecular details between the homotypic
and heterotypic nucleoprotein complexes, although the main
oligomerization motifs are similarly utilized in both. Nevertheless,
higher-resolution structural information from the heterotypic NP
complex is necessary to conﬁrm these conjectures.
How could the heterotypic NP complex interfere with IAV poly-
merase? We showed here that, in the absence of other polymerase
subunits, BNP disrupts essential interaction between ANP and PB2 but
does not interfere with PB1. However, ANP mutants that are defective
in polymerase binding showed minimal effects on BNP binding. These
data together suggested that BNP could interfere with the ANP–PB2
complex by sequestering ANP from PB2, but the ANP–BNP binding
interface does not entirely overlap with the ANP–PB2 binding inter-
face. Although characterization of the complete NP–polymerase
binding interfaces is still pending, these data argue for an alternative
inhibition model in which BNP binding possibly causes structural or
conformational changes on ANP that prohibit PB2 binding. Further-
more, co-immunoprecipitation shows that BNP cannot interact with
IAV's PB2 (Jaru-ampornpan et al., 2014). Therefore, despite the
closeness in the assembly mechanism or the gross structures of these
nucleoprotein complexes, the intertypic NP complexes could not
functionally replace the homotypic ANP complexes and would result
in decreases in IAV replication.
Our study of the BNP's anti-IAV effect using several approaches
has revealed subtlety in BNP-mediated IAV inhibition mechanism as
well as achievable potency of BNP. IAVs replicated 105 times less
efﬁciently in MDCK-BNP cells, in which BNP protein is available at a
substantial level prior to infection. However, the effect of BNP on
growth kinetics of the chimeric ΔPB2-PR8-BNP viruses was appre-
ciably masked, supposedly due to two critical factors: BNP timing
and expression levels relative to ANP. While the incoming ΔPB2-
PR8-BNP chimeric viruses carry functional polymerase complexes
and numerous copies of ANP, they do not package BNP protein into
the particles (data not shown), already putting them at a disadvan-
tage both in terms of timing and amount of BNP. Compared to BNP
expression in MDCK-BNP cells (under the SFFV promoter), BNP
Fig. 7. BNP differentially affects other IAV strains but does not inhibit VSV replication. (A) HEK293T cells were co-transfected with pHW2000-BNP and pHW2000-ANP-Myc
from H1N1 (PR8), H6N1 and H3N2 (500 ng each). Cell lysates were subjected to co-IP by anti-Myc antibody and analyzed by Western blots with indicated antibodies. IP,
immunoprecipitate complex; input, 10% of the input lysate. Figure is representative of three independent experiment, and bar graph denotes quantiﬁcation of BNP pulled
down by ANP-Myc. The ‘prey’ bands (anti-BNP) were normalized by their corresponding ‘bait’ bands (anti-Myc) from the same lane. Values are displayed relative to the H1N1
condition. (B) IAV polymerase inhibition assay was performed as described in section Materials and Methods. The polymerases were reconstituted from PB2, PB1, PA and NP
genes derived from each strain. Values are relative to IAV polymerase activity of each strain in the presence of the pHW2000 vector (‘–BNP’). (C) Growth analysis of H1N1
(circles), H6N1 (squares) and H3N2 (triangles) in MDCK (solid lines) or MDCK-BNP (dashed lines) cells (MOI¼0.001). (D) BNP does not inhibit VSV replication. Growth
analysis of VSV in MDCK (open circles, solid line) or MDCK-BNP (closed circles, dashed line) cells (MOI¼0.001).
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expression under the PR8 PB2 UTR is noticeably smaller (Fig. 4E).
Therefore, in the case of infection by chimeric viruses, the much
greater amount of ANP produced under its native UTR during the
replication cycle will eventually overwhelm BNP. Taken together,
these results demonstrated that timing and expression level of BNP
could profoundly affect its anti-IAV property. These data are also
consistent with previous work which demonstrated that a large
amount of ANP could reverse BNP's inhibitory effect and that IBV
could no longer suppress IAV replication if IAV infection was
established at least two hours prior to IBV infection (Wanitchang
et al., 2012). Notably, the observation that BNP's antiviral effect is
intimately dependent on its expression level is a hallmark of a
competitive nature of the proposed inhibition mechanism. Never-
theless, during co-infection, other mechanisms besides BNP's inhi-
bitory effect on IAV polymerase could contribute to intertypic
interference (Mikheeva and Ghendon, 1982; Aoki et al., 1984;
Muster et al., 1991; Baker et al., 2014; Iwatsuki-Horimoto et al.,
2008; Wunderlich et al., 2010).
Although attractive, this proposed mechanism might not recapitu-
late every aspect of BNP's inhibitory effect. Especially, the effect of BNP
on the H3N2 virus is interesting. Co-immunoprecipitation showed that
ANP from H3N2 could bind to BNP, albeit slightly less efﬁciently.
Nevertheless, we could observe a sizable relief in BNP's inhibitory effect
toward H3N2 polymerase and its growth. These data might hint at
contributions from other viral factors, especially the polymerase
subunits, that may modulate the inhibitory effect of BNP. In addition,
nucleoprotein interacts with a myriad of host proteins as well as other
viral proteins during the viral life cycle (Portela and Digard, 2002),
opening up possibilities for modulation of BNP's inhibition.
In conclusion, we have provided additional mechanistic details
regarding BNP-mediated IAV polymerase inhibition and demon-
strated the antiviral effect of BNP. As shown in this report, IAV
growth suppression exhibited by BNP could be substantial upon
appropriate timing and expression level. In line with the proposed
mechanism of action, BNP's inhibitory effect is speciﬁc to IAVs
and could vary in degree upon the identity of the tested IAV
strains. More investigation is underway to assess the potential of
developing BNP, or parts of the protein, into a novel potent and
broad-spectrum anti-IAV agent. On the other hand, lessons from
molecular study of BNP's viral suppression mechanism like this
work could beneﬁt the design of novel antiviral small molecules
targeting ANP.
Materials and methods
Biological materials
Construction of plasmids expressing tagged proteins was
described previously (Jaru-ampornpan et al., 2014). Point muta-
tions in ANP and BNP were constructed by PCR-based site-directed
mutagenesis. The following antibodies were used according to the
manufacturer's recommendations: anti-ANP and anti-BNP (South-
ern Biotechnology), anti-Myc (Invitrogen), anti-FLAG (Cell Signal-
ing Technology), HRP-conjugated goat-anti-mouse IgG and goat-
anti-rabbit IgG (Santa Cruz Biotechnology) and FITC-labeled goat-
anti-mouse IgG for immunoﬂuorescence (Abcam). Human
Embryonic Kidney (HEK) 293T and Madin–Darby Canine Kidney
(MDCK) cells were maintained in Opti-MEM supplemented with
10% fetal bovine serum (FBS). The inﬂuenza virus strains used in
this study were A/Puerto Rico/8/34 (H1N1) (IAV), A/Uruguay/716/
2007 (H3N2), A/duck/Suphanburi/AI157/2005 (H6N1), and B/Lee/
40 (IBV). Recombinant vesicular stomatitis virus (VSV) was derived
from VSV Indiana serotype and described elsewhere (Diaz et al.,
2007).
Co-immunoprecipitation (co-IP)
Co-immunoprecipitation was performed as described pre-
viously (Jaru-ampornpan et al., 2014). In brief, HEK293T cells were
transfected with indicated plasmids (500 ng each, unless other-
wise speciﬁed). Cells were lysed at 48 h post-transfection with co-
IP buffer [50 mM Tris–HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 1%
NP-40 supplemented with protease inhibitor cocktail (Sigma-
Aldrich)]. Clariﬁed lysates were incubated with agarose beads
conjugated with primary antibodies (Thermo Scientiﬁc). The IP
complex was washed three times in co-IP buffer supplemented
with 250 mM NaCl, eluted by boiling the beads in SDS-PAGE gel
loading buffer, and analyzed by Western blotting. Co-IP negative
controls using mouse IgG coupled to agarose beads showed no
bands for both bait and prey proteins in elution for all the
interaction pairs tested in this study (Supplementary Fig. 1).
Figures are representative of three independent experiments.
Direct comparisons in the same panels were performed in side-
by-side experiments. Quantiﬁcation of co-IP bands was performed
with ImageJ (Schneider et al., 2012) and represents average7S.D.
from three independent experiments.
Minigenome assay
The IAV and IBV minigenome assays were performed as
previously described (Wanitchang et al., 2012). Brieﬂy, HEK293T
cells were transfected with a set of plasmids expressing PB2, PB1,
PA, NP, and an RNA polymerase I-driven plasmid expressing
negative-sense viral RNA encoding secreted neuraminidase to
reconstitute IAV or IBV vRNPs. Polymerase activity was determined
by quantiﬁcation of neuraminidase activity to convert 20-(4-
Methylumbelliferyl)-α-D-N-acetylneuraminic acid (Sigma-Aldrich)
to a ﬂuorescent product (Potier et al., 1979). In IAV inhibition
experiments, plasmids expressing BNP variants were co-
transfected to determine their ability to suppress expression of
the neuraminidase gene. Values are expressed relative to IAV
polymerase activity in the absence of BNP and are averages7S.
D. from three independent experiments.
Immunoﬂuorescence
HEK293T cells were seeded on chamber slides and transfected
with plasmids expressing Myc-tagged BNP variants. At 16 h post-
transfection, cells were ﬁxed and permeabilized with 100% ice-
cold acetone for 5 min and blocked with phosphate-buffered
saline (PBS) supplemented with 1% bovine serum albumin (BSA)
and 10% FBS. After 1-h incubation with anti-Myc antibody, per-
meabilized cells were washed with PBS supplemented with 0.05%
tween-20. FITC-conjugated goat-anti-mouse IgG was then added.
After ﬁve washes, the ﬂuorescence images were taken on ﬂuores-
cence microscope (Olympus). Nuclei were stained with DAPI.
Construction of MDCK cell lines expressing inﬂuenza viral proteins
To construct lentiviral vectors expressing inﬂuenza virus proteins,
IAV PB2 or BNP genes were ampliﬁed from pHW2000-based
plasmids. The PCR products were digested and inserted into BamHI
and XhoI sites of the pSIN-CSGW-UbEm lentivitral vector. Expression
of inﬂuenza virus genes was driven by the spleen focus-forming
virus (SFFV) promoter. The lentiviruses encoding inﬂuenza virus
proteins were recovered based on the method described previously
(Schmeckpeper et al., 2009). Brieﬂy, HEK293T cells were transfected
with lentiviral vectors in combination with a packaging plasmid
(pCMV-ΔR8.91 encoding the packaging proteins Gag-Pol, Rev, Tat)
and an envelope expression plasmid (pMD.G encoding the VSV
glycoprotein). Viral supernatant was harvested at 48 h and ﬁltered
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through a 0.45 μm ﬁlter. Subsequently, the lentiviruses were trans-
duced into MDCK cells. Single clones of MDCK cells expressing
inﬂuenza viral proteins were identiﬁed and selected from the
population pool based on emerald ﬂuorescence intensity by FACS
analysis (BD FACSAria II, BD Biosciences). For MDCK-BNP series,
clones were further selected based on similar expression of BNP
variants (Supplementary Fig. 2).
Reverse genetics of mCherry- or BNP-expressing inﬂuenza viruses
Reverse genetics of recombinant IAV harboring mCherry or BNP
in place of the original PB2 segment was carried out with bi-
directional pHW2000 plasmids containing the cDNAs of PR8
genes. Brieﬂy, the pHW2000-PB2 plasmid was ﬁrst modiﬁed to
contain variants of BNPs or mCherry ﬂanked by PB2 30- and 50-
UTRs including putative packaging signals (120 nucleotides of the
coding sequence at the 30 end and 336 nucleotides of the coding
sequence of the 50 end) (Uraki et al., 2013). The resulting plasmids
were designated pPB2(120)BNP(336) or pPB2(120)mCherry(336).
To generate recombinant IAV, pPB2(120)BNP(336) or pPB2(120)
mCherry(336) was mixed with pHW2000 plasmids expressing
PB1, PA, HA, NP, NA, M and NS genes (500 ng each). In addition,
pCAGGS expressing PB2 (1 μg) was included in the plasmid
mixture. The combined plasmids were transfected into HEK293T-
MDCK-PB2 co-culture. At 24 h post-transfection, TPCK-trypsin
(2 μg/ml) was added to the supernatant. At 72 h post-transfection,
supernatants containing recombinant IAV were harvested and
further propagated in MDCK-PB2 cells.
Viral growth analysis
MDCK cells were infected with each virus strain at 0.001
multiple of infectivity (MOI). One h post-adsorption, the cells
were washed once with PBS, and 2 ml of fresh Opti-MEM contain-
ing 2 μg/ml TPCK-trypsin was added to each well. The supernatant
was collected at indicated time points post-infection for virus
titration by plaque assay. For plaque assay, monolayers of MDCK
cells (or MDCK-PB2 cells for Fig. 4B) were adsorbed for 1 h with
1 ml of 10-fold serially diluted virus. After removal of inocula, the
cells were washed with PBS and covered with 3 ml of agar media
(0.9% Bacto-agar, 1 MEM, 20 mg/ml BSA, 0.225 mg/ml sodium
bicarbonate and 2 μg/ml TPCK-trypsin). After 72-h incubation at
37 1C, the agar mix was removed and the cells were stained with a
0.1% crystal violet solution. Plaques were counted, and the num-
bers reported are averages of three independent experiments.
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